Results 191 to 200 of about 617,141 (296)
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis. [PDF]
Tavaglione F, Loomba R.
europepmc +1 more source
Multifaceted burden of short bowel syndrome for patients and caregivers: The landmark survey
Abstract Background Short bowel syndrome is a debilitating condition often requiring long‐term parenteral support to maintain hydration, nutrition, and survival. Methods As part of the noninterventional, cross‐sectional Landmark Survey study, we evaluated burdens associated with short bowel syndrome and parenteral support dependency from patient and ...
Jenny E. Harrison +11 more
wiley +1 more source
The Evolution of Medications for Obesity Management. [PDF]
Gill J, Sumithran P.
europepmc +1 more source
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter +14 more
wiley +1 more source
Targeting glucagon signaling in metabolic disorders, functional insights from zebrafish receptor knockouts. [PDF]
Al Madhoun A +17 more
europepmc +1 more source
How the Sea Salt Chocolate Cookie Became a Thing: The Role of Flavor Pairing in Obesity
Proposed framework illustrating how flavor pairing and multisensory flavor architecture may sustain hedonic eating through enhanced palatability, reward preservation, delayed sensory‐specific satiety, and post‐ingestive signaling, thereby promoting excess energy intake and obesity risk.
Mohammed Ayyad, Eugene Kim
wiley +1 more source
The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. [PDF]
Patil M +4 more
europepmc +1 more source
ABSTRACT Objective Incretin‐based obesity therapies (IBTs), especially GLP‐1 receptor agonists (GLP‐1 RAs), effectively treat obesity and improve comorbidities. However, their impact on energy metabolism is unclear. A recent case of acute generalized muscle weakness in a patient with mitochondrial myopathy after tirzepatide exposure raises concerns ...
Bryn Falahee +2 more
wiley +1 more source

